A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia

Sponsor
Janssen Research & Development, LLC
Study ID
NCT07541261
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The main purpose of this study is to evaluate treatment persistence of guselkumab (that is how long a person keeps taking their prescribed medicine or continues with their treatment plan without stopping) in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.

Key Dates

First listed
Apr 21, 2026
Start date
May 12, 2026
Status verified
Jun 2026
Primary completion
Jan 2, 2029
Completion
Jan 29, 2029

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Moderate-to-Severe Ulcerative Colitis (UC) or Crohn's Disease (CD): Guselkumab
    Participants with confirmed diagnosis of moderate-to-severe UC or CD treated with guselkumab as per standard clinical practice will be enrolled. No drug will be provided as part of this study. Only data available from clinical practice, through routine therapeutic procedures and evaluation assessments will be collected within this study.

Primary Outcome Measure

Time to Guselkumab Discontinuation [ Time Frame: Up to Week 96 ]

Central Contacts

Find similar trials

Nationwide
Crohn's disease trialsGastroenterology trialsInflammatory bowel disease trialsAutoimmune disease trials

Related Studies